|
Inflammatory mediator (mean ± SD)
|
LPS + vehicle
|
LPS + OLDA
|
P (Mann–Whitney)
|
|---|
|
IL-1β (pg/ml)
|
101 ± 44
|
40 ± 29
|
0.0005χ
|
|
IL-2 (pg/ml)
|
9.3 ± 4.7
|
6.6 ± 2
|
0.04χ
|
|
IL-4 (pg/ml)
|
1.9 ± 0.24
|
1.7 ± 0.28
|
0.06
|
|
IL-5 (pg/ml)
|
29 ± 6.1
|
15 ± 8.4
|
0.0003χ
|
|
IL-6 (ng/ml)
|
927 ± 26
|
477 ± 196
|
< 0.0001χ
|
|
IL-9 (pg/ml)
|
165 ± 26
|
60 ± 28
|
< 0.0001χ
|
|
IL-10 (ng/ml)
|
2.1 ± 0.5
|
13 ± 7.9
|
< 0.0001θ
|
|
IL-12p70 (pg/ml)
|
26 ± 4.7
|
19 ± 1.8
|
0.0001χ
|
|
IL-13 (pg/ml)
|
4.7 ± 1.1
|
3.6 ± 0.32
|
0.003 χ
|
|
IL-17A (pg/ml)
|
4.4 ± 2
|
3.4 ± 1.2
|
0.26
|
|
IL-18 (ng/ml)
|
2.4 ± 0.17
|
2.2 ± 0.15
|
0.06
|
|
IL-22 (ng/ml)
|
19 ± 7
|
2.8 ± 2.3
|
< 0.0001χ
|
|
IL-23 (pg/ml)
|
21 ± 16
|
15 ± 17
|
0.0158χ
|
|
IL-27 (pg/ml)
|
100 ± 29
|
41 ± 22
|
< 0.0001χ
|
|
GM-CSF (pg/ml)
|
22 ± 2.9
|
15 ± 1.8
|
< 0.0001χ
|
|
TNF-α (ng/ml)
|
1.1 ± 0.33
|
0.61 ± 0.13
|
< 0.0001χ
|
|
IFN-γ (pg/ml)
|
13 ± 4.7
|
8.6 ± 1.7
|
0.01χ
|
|
MCP-1/CCL-2 (ng/ml)
|
91.3 ± 22
|
55.7 ± 19
|
< 0.0001χ
|
|
MIP-1α/CCL-3 (ng/ml)
|
1.2 ± 0.2
|
0.75 ± 0.2
|
< 0.0001χ
|
|
MIP-1β/CCL-4 (ng/ml)
|
5.8 ± 1.3
|
5.1 ± 2
|
0.52
|
|
RANTES/CCL-5 (ng/ml)
|
0.8 ± 0.17
|
0.4 ± 0.15
|
< 0.0001χ
|
|
MCP-3/CCL-7 (ng/ml)
|
1.2 ± 0.16
|
0.99 ± 0.1
|
0.0028χ
|
|
Eotaxin/CCL-11 (ng/ml)
|
1 ± 0.12
|
0.81 ± 0.09
|
< 0.0001χ
|
|
Gro-α/CXCL-1 (ng/ml)
|
12 ± 5.7
|
6.1 ± 4.3
|
0.016χ
|
|
IP-10/CXCL-10 (pg/ml)
|
476 ± 37
|
359 ± 75
|
< 0.0001χ
|
- Wild-type mice were treated with LPS (1 mg/kg, i.v.) and immediately thereafter with OLDA (10 mg/kg, i.v.) or vehicle (i.v.). Cytokines and chemokines were quantified in plasma at T = 2 h using Procartaplex™ immunoassay technology (Thermo Fisher Scientific) (9- to 12-week male and female, n = 11–12/group)
- θIndicates significant upregulation
- χIndicates significant downregulation
